IP Library Granted Patent US 9,637,538
Granted Patent B2
US 9,637,538 · App. 13/869,477 · Granted May 2, 2017

Anti-HLA monoclonal chimeric immunoglobulin, process and kit employing such a monoclonal chimeric immunoglobulin

Inventors: Antoine Blancher (Toulouse, FR); Nicolas Congy (La Croix Falgarde, FR); Jean-Gerard Tiraby (Toulouse, FR); Daniel Drocourt (Toulouse, FR)
Assignees: UNIVERSITE PAUL SABATIER TOULOUSE III; CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE; INVIVOGEN
C07K16/18C07K16/2833G01N33/56977G01N33/6893C07K2317/24C07K2317/34
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,637,538
App. No.
13/869,477
Granted
May 2, 2017
Kind
B2
Abstract

A monoclonal chimeric immunoglobulin wherein the heavy chains and the light chains are human by nature in their constant parts, in particular, the heavy chain constant parts are chosen from the group formed of the heavy chain constant parts of an IgA, of an IgG or of an IgM and the light chain constant parts are chosen from the group formed of the kappa chains and the lambda chains, and the light chain and the heavy chain variable parts are chosen from the group formed of monoclonal antibodies specific to monomorphic epitopes of HLA class I antigens and monoclonal antibodies specific to monomorphic epitopes of HLA class II antigens. A process for standardization of the screening and for quantification of anti-HLA antibodies in a liquid medium is also described.

Claims (14)

1. A monoclonal chimeric comprising formed of:

(i) two polypeptide chains, called heavy chains (H), of molecular weight from 40 kDa to 60 kDa, and

(ii) two polypeptide chains, called light chains (L), of molecular weight from 20 kDa to 30 kDa,

wherein

each heavy chain (H) comprises:

a heavy chain variable region (VH) of a monoclonal antibody chosen from the group consisting of monoclonal antibodies specific to monomorphic epitopes of HLA class II antigens, and

a heavy chain constant region (CH) of a human immunoglobulin chosen from the group consisting of IgAs, IgGs and IgMs,

and wherein

at least one light chain (L) consists of the sequence SEQ ID NO: 5, and

at least one heavy chain (H) is selected from the group consisting of SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8.

2. The monoclonal antibody according to claim 1 , wherein the at least one heavy chain (H) consists of the sequence of SEQ ID NO: 6.

3. The monoclonal antibody according to claim 1 , wherein the at least one heavy chain (H) consists of the sequence of SEQ ID NO: 7.

4. The monoclonal antibody according to claim 1 , wherein the at least one heavy chain (H) consists of the sequence of SEQ ID NO: 8.

5. A kit for the quantification of anti-HLA antibodies in a liquid medium, said kit comprising the monoclonal chimeric immunoglobulin of claim 1 .

Assignments (2)
CHANGE OF NAME Recorded Feb 24, 2014
From: CAYLA
To: INVIVOGEN
Reel/Frame 032328/0950 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 26, 2013
From: BLANCHER, ANTOINE; CONGY, NICOLAS; TIRABY, JEAN-GERARD; DROCOURT, DANIEL
To: UNIVERSITE PAUL SABATIER TOULOUSE III; CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE; CAYLA
Reel/Frame 030296/0660 →
Continuity (2)
Provisional Application 61639244 · Apr 27, 2012
Related Publication 20130288387A1 · Oct 31, 2013